A randomized trial of 24 versus 48 weeks of peginterferon α-2a in patients infected with chronic hepatitis C virus genotype 2 or low viral load genotype 1: A multicenter national study in Japan

Yoshiaki Iwasaki, Yasushi Shiratori, Shuhei Hige, Shuhei Nishiguchi, Hitoshi Takagi, Morikazu Onji, Haruhiko Yoshida, Namiki Izumi, Yutaka Kohgo, Kyosuke Yamamoto, Nobuhiro Sato, Akitaka Shibuya, Hidetsugu Saito, Michio Sata, Kazuyuki Suzuki, Shuichi Kaneko, Mitsuhiko Moriyama, Masao Omata

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

In a country such as Japan with the average age of patients with chronic hepatitis C treated with antivirals sometimes well above 60 years, the standard combination therapy is not well tolerated. In this randomized, prospective, controlled trial, we investigated the efficacy of 24-week peginterferon α monotherapy for easy-to-treat patients. A total of 132 patients chronically infected with hepatitis C virus (HCV) genotype 2 (n = 115) or low viral load HCV genotype 1 (<100 kIU/ml, n = 17) were treated with peginterferon α-2a (180 μg/week). Patients with a rapid virological response (RVR, HCV RNA negative or <500 IU/ ml at week 4) were randomized for a total treatment duration of 24 (group A) or 48 (group B) weeks. Patients who did not show RVR (group C) were treated for 48 weeks. Sustained virological response (SVR) was assessed by qualitative reverse-transcription polymerase chain reaction. One hundred eight of 132 (82%) patients with RVR were randomized. SVR rates were 60% (group A), 79% (group B), and 27% (group C), respectively. Similar SVR rates were achieved in patients infected with HCV genotype 2 with low pretreatment viral load (<1000 kIU/ml) in group A (81%) and group B (79%) (P = 0.801), whereas in those with higher viral load (≥1000 kIU/ml), a lower SVR rate was identified in group A (26%) than in group B (67%) (P = 0.041). In conclusion, in patients infected with HCV genotype 2 and pretreatment viral load below 1000 kIU/ml who achieve RVR, 24-week treatment with peginterferon α-2a alone is clinically sufficient. Those who show no RVR or have higher baseline viral load, require alternative therapies.

Original languageEnglish
Pages (from-to)468-479
Number of pages12
JournalHepatology International
Volume3
Issue number3
DOIs
Publication statusPublished - 2009

Fingerprint

Chronic Hepatitis C
Viral Load
Hepacivirus
Multicenter Studies
Japan
Genotype
Complementary Therapies
Reverse Transcription
Antiviral Agents
Therapeutics
Randomized Controlled Trials
RNA
Polymerase Chain Reaction

Keywords

  • Chronic hepatitis C
  • Genotype 2
  • Peginterferon-α monotherapy
  • Pretreatment viral load
  • Randomized trial
  • Rapid virological response

ASJC Scopus subject areas

  • Hepatology

Cite this

A randomized trial of 24 versus 48 weeks of peginterferon α-2a in patients infected with chronic hepatitis C virus genotype 2 or low viral load genotype 1 : A multicenter national study in Japan. / Iwasaki, Yoshiaki; Shiratori, Yasushi; Hige, Shuhei; Nishiguchi, Shuhei; Takagi, Hitoshi; Onji, Morikazu; Yoshida, Haruhiko; Izumi, Namiki; Kohgo, Yutaka; Yamamoto, Kyosuke; Sato, Nobuhiro; Shibuya, Akitaka; Saito, Hidetsugu; Sata, Michio; Suzuki, Kazuyuki; Kaneko, Shuichi; Moriyama, Mitsuhiko; Omata, Masao.

In: Hepatology International, Vol. 3, No. 3, 2009, p. 468-479.

Research output: Contribution to journalArticle

Iwasaki, Y, Shiratori, Y, Hige, S, Nishiguchi, S, Takagi, H, Onji, M, Yoshida, H, Izumi, N, Kohgo, Y, Yamamoto, K, Sato, N, Shibuya, A, Saito, H, Sata, M, Suzuki, K, Kaneko, S, Moriyama, M & Omata, M 2009, 'A randomized trial of 24 versus 48 weeks of peginterferon α-2a in patients infected with chronic hepatitis C virus genotype 2 or low viral load genotype 1: A multicenter national study in Japan', Hepatology International, vol. 3, no. 3, pp. 468-479. https://doi.org/10.1007/s12072-009-9134-1
Iwasaki, Yoshiaki ; Shiratori, Yasushi ; Hige, Shuhei ; Nishiguchi, Shuhei ; Takagi, Hitoshi ; Onji, Morikazu ; Yoshida, Haruhiko ; Izumi, Namiki ; Kohgo, Yutaka ; Yamamoto, Kyosuke ; Sato, Nobuhiro ; Shibuya, Akitaka ; Saito, Hidetsugu ; Sata, Michio ; Suzuki, Kazuyuki ; Kaneko, Shuichi ; Moriyama, Mitsuhiko ; Omata, Masao. / A randomized trial of 24 versus 48 weeks of peginterferon α-2a in patients infected with chronic hepatitis C virus genotype 2 or low viral load genotype 1 : A multicenter national study in Japan. In: Hepatology International. 2009 ; Vol. 3, No. 3. pp. 468-479.
@article{d0639c9255c0482d9f640e73ca78081e,
title = "A randomized trial of 24 versus 48 weeks of peginterferon α-2a in patients infected with chronic hepatitis C virus genotype 2 or low viral load genotype 1: A multicenter national study in Japan",
abstract = "In a country such as Japan with the average age of patients with chronic hepatitis C treated with antivirals sometimes well above 60 years, the standard combination therapy is not well tolerated. In this randomized, prospective, controlled trial, we investigated the efficacy of 24-week peginterferon α monotherapy for easy-to-treat patients. A total of 132 patients chronically infected with hepatitis C virus (HCV) genotype 2 (n = 115) or low viral load HCV genotype 1 (<100 kIU/ml, n = 17) were treated with peginterferon α-2a (180 μg/week). Patients with a rapid virological response (RVR, HCV RNA negative or <500 IU/ ml at week 4) were randomized for a total treatment duration of 24 (group A) or 48 (group B) weeks. Patients who did not show RVR (group C) were treated for 48 weeks. Sustained virological response (SVR) was assessed by qualitative reverse-transcription polymerase chain reaction. One hundred eight of 132 (82{\%}) patients with RVR were randomized. SVR rates were 60{\%} (group A), 79{\%} (group B), and 27{\%} (group C), respectively. Similar SVR rates were achieved in patients infected with HCV genotype 2 with low pretreatment viral load (<1000 kIU/ml) in group A (81{\%}) and group B (79{\%}) (P = 0.801), whereas in those with higher viral load (≥1000 kIU/ml), a lower SVR rate was identified in group A (26{\%}) than in group B (67{\%}) (P = 0.041). In conclusion, in patients infected with HCV genotype 2 and pretreatment viral load below 1000 kIU/ml who achieve RVR, 24-week treatment with peginterferon α-2a alone is clinically sufficient. Those who show no RVR or have higher baseline viral load, require alternative therapies.",
keywords = "Chronic hepatitis C, Genotype 2, Peginterferon-α monotherapy, Pretreatment viral load, Randomized trial, Rapid virological response",
author = "Yoshiaki Iwasaki and Yasushi Shiratori and Shuhei Hige and Shuhei Nishiguchi and Hitoshi Takagi and Morikazu Onji and Haruhiko Yoshida and Namiki Izumi and Yutaka Kohgo and Kyosuke Yamamoto and Nobuhiro Sato and Akitaka Shibuya and Hidetsugu Saito and Michio Sata and Kazuyuki Suzuki and Shuichi Kaneko and Mitsuhiko Moriyama and Masao Omata",
year = "2009",
doi = "10.1007/s12072-009-9134-1",
language = "English",
volume = "3",
pages = "468--479",
journal = "Hepatology International",
issn = "1936-0533",
publisher = "Springer New York",
number = "3",

}

TY - JOUR

T1 - A randomized trial of 24 versus 48 weeks of peginterferon α-2a in patients infected with chronic hepatitis C virus genotype 2 or low viral load genotype 1

T2 - A multicenter national study in Japan

AU - Iwasaki, Yoshiaki

AU - Shiratori, Yasushi

AU - Hige, Shuhei

AU - Nishiguchi, Shuhei

AU - Takagi, Hitoshi

AU - Onji, Morikazu

AU - Yoshida, Haruhiko

AU - Izumi, Namiki

AU - Kohgo, Yutaka

AU - Yamamoto, Kyosuke

AU - Sato, Nobuhiro

AU - Shibuya, Akitaka

AU - Saito, Hidetsugu

AU - Sata, Michio

AU - Suzuki, Kazuyuki

AU - Kaneko, Shuichi

AU - Moriyama, Mitsuhiko

AU - Omata, Masao

PY - 2009

Y1 - 2009

N2 - In a country such as Japan with the average age of patients with chronic hepatitis C treated with antivirals sometimes well above 60 years, the standard combination therapy is not well tolerated. In this randomized, prospective, controlled trial, we investigated the efficacy of 24-week peginterferon α monotherapy for easy-to-treat patients. A total of 132 patients chronically infected with hepatitis C virus (HCV) genotype 2 (n = 115) or low viral load HCV genotype 1 (<100 kIU/ml, n = 17) were treated with peginterferon α-2a (180 μg/week). Patients with a rapid virological response (RVR, HCV RNA negative or <500 IU/ ml at week 4) were randomized for a total treatment duration of 24 (group A) or 48 (group B) weeks. Patients who did not show RVR (group C) were treated for 48 weeks. Sustained virological response (SVR) was assessed by qualitative reverse-transcription polymerase chain reaction. One hundred eight of 132 (82%) patients with RVR were randomized. SVR rates were 60% (group A), 79% (group B), and 27% (group C), respectively. Similar SVR rates were achieved in patients infected with HCV genotype 2 with low pretreatment viral load (<1000 kIU/ml) in group A (81%) and group B (79%) (P = 0.801), whereas in those with higher viral load (≥1000 kIU/ml), a lower SVR rate was identified in group A (26%) than in group B (67%) (P = 0.041). In conclusion, in patients infected with HCV genotype 2 and pretreatment viral load below 1000 kIU/ml who achieve RVR, 24-week treatment with peginterferon α-2a alone is clinically sufficient. Those who show no RVR or have higher baseline viral load, require alternative therapies.

AB - In a country such as Japan with the average age of patients with chronic hepatitis C treated with antivirals sometimes well above 60 years, the standard combination therapy is not well tolerated. In this randomized, prospective, controlled trial, we investigated the efficacy of 24-week peginterferon α monotherapy for easy-to-treat patients. A total of 132 patients chronically infected with hepatitis C virus (HCV) genotype 2 (n = 115) or low viral load HCV genotype 1 (<100 kIU/ml, n = 17) were treated with peginterferon α-2a (180 μg/week). Patients with a rapid virological response (RVR, HCV RNA negative or <500 IU/ ml at week 4) were randomized for a total treatment duration of 24 (group A) or 48 (group B) weeks. Patients who did not show RVR (group C) were treated for 48 weeks. Sustained virological response (SVR) was assessed by qualitative reverse-transcription polymerase chain reaction. One hundred eight of 132 (82%) patients with RVR were randomized. SVR rates were 60% (group A), 79% (group B), and 27% (group C), respectively. Similar SVR rates were achieved in patients infected with HCV genotype 2 with low pretreatment viral load (<1000 kIU/ml) in group A (81%) and group B (79%) (P = 0.801), whereas in those with higher viral load (≥1000 kIU/ml), a lower SVR rate was identified in group A (26%) than in group B (67%) (P = 0.041). In conclusion, in patients infected with HCV genotype 2 and pretreatment viral load below 1000 kIU/ml who achieve RVR, 24-week treatment with peginterferon α-2a alone is clinically sufficient. Those who show no RVR or have higher baseline viral load, require alternative therapies.

KW - Chronic hepatitis C

KW - Genotype 2

KW - Peginterferon-α monotherapy

KW - Pretreatment viral load

KW - Randomized trial

KW - Rapid virological response

UR - http://www.scopus.com/inward/record.url?scp=68949152547&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=68949152547&partnerID=8YFLogxK

U2 - 10.1007/s12072-009-9134-1

DO - 10.1007/s12072-009-9134-1

M3 - Article

C2 - 19669250

AN - SCOPUS:68949152547

VL - 3

SP - 468

EP - 479

JO - Hepatology International

JF - Hepatology International

SN - 1936-0533

IS - 3

ER -